CibusCBUS
CBUS
About: Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
Employees: 159
0
Funds holding %
of 7,433 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
10.63% less ownership
Funds ownership: 36.74% [Q1] → 26.11% (-10.63%) [Q2]
13% less funds holding
Funds holding: 68 [Q1] → 59 (-9) [Q2]
23% less capital invested
Capital invested by funds: $22.6M [Q1] → $17.4M (-$5.13M) [Q2]
28% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 25
39% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 18
Research analyst outlook
We haven’t received any recent analyst ratings for CBUS.
Financial journalist opinion
Based on 4 articles about CBUS published over the past 30 days
Neutral
Seeking Alpha
1 week ago
Cibus, Inc. (CBUS) Q2 2025 Earnings Call Transcript
Cibus, Inc. (NASDAQ:CBUS ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Cornelis Broos - Interim Chief Financial Officer Gregory F. Gocal - Co-Founder, Chief Scientific Officer & Executive VP Peter R.
Negative
Zacks Investment Research
1 week ago
Cibus (CBUS) Reports Q2 Loss, Lags Revenue Estimates
Cibus (CBUS) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to a loss of $1.14 per share a year ago.
Neutral
GlobeNewsWire
1 week ago
Cibus Reports Second Quarter Financial Results and Provides Year-to-Date Business Update for 2025
Streamlining operational focus on Rice herbicide tolerance traits and partner-funded and/or supported programs, expected to reduce annual cash usage to approximately $30 million by 2026
Neutral
GlobeNewsWire
3 weeks ago
Cibus to Report Second Quarter 2025 Financial Results on August 14, 2025 After the Market Close and Host Conference Call
SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that the company will report second quarter 2025 financial results on Thursday, August 14, 2025. Cibus' management team will host a conference call and audio webcast at 4:30 p.m.
Neutral
GlobeNewsWire
2 months ago
The U.S. Food and Drug Administration Completes Review of Cibus' Altered Lignin Alfalfa Developed in Partnership with S&W Seed Company for use in Livestock Feed
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural technology company that develops and licenses plant traits to seed companies, announced today that it has completed the U.S. Food and Drug Administration's (FDA) Plant Biotechnology Consultation Program for its altered lignin alfalfa trait with the FDA notifying Cibus that it has no further questions concerning the use of altered lignin alfalfa in food or feed. To develop altered lignin alfalfa, Cibus (formerly Calyxt, Inc.) collaborated with S&W Seed Company to identify an alfalfa trait with an altered lignin profile providing potential increased nutrient availability for livestock.
Neutral
GlobeNewsWire
2 months ago
Cibus and John Innes Centre Announce Ongoing Collaboration with Potential to Revolutionize Fertilizer Use in Farming
Researchers at the John Innes Centre (JIC) have discovered a genetic mutation with the potential to enhance nutrient uptake and reduce the need for artificial fertilizers Cibus and JIC have agreed on a collaboration with the potential to introduce the trait into several commercial crops Cibus previously announced the successful editing of Canola plants with this mutation and looks forward to further testing and trait validation SAN DIEGO, June 12, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. ("Cibus" or the "Company") (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today confirmed its continuing collaboration with the John Innes Centre (JIC). Cibus applauds the JIC breakthrough discovery, published earlier this year in the journal Nature, of a biological mechanism that makes plant roots more welcoming to beneficial soil microbes.
Neutral
GlobeNewsWire
2 months ago
Cibus, Inc. Announces Closing of $27.5 Million Public Offering
SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced the closing of its previously announced public offering of 15,714,285 shares of its Class A Common Stock, at a purchase price of $1.75 per share, including to institutional and strategic investors, as well as the Chairman of Cibus' board of directors (5,714,286 shares).
Neutral
GlobeNewsWire
2 months ago
USDA Designates Cibus' Herbicide Tolerance Canola Trait HT2 as Not Regulated Under USDA's Biotechnology Regulations
This action follows the USDA's recent designation of Cibus' disease resistance traits in Canola as not regulated, continuing Cibus' product development momentum in the globally important Canola crop This action follows the USDA's recent designation of Cibus' disease resistance traits in Canola as not regulated, continuing Cibus' product development momentum in the globally important Canola crop
Neutral
GlobeNewsWire
2 months ago
Cibus, Inc. Announces Pricing of $27.5 Million Public Offering
SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced the pricing of its previously announced public offering of 15,714,285 shares of its Class A Common Stock, at a purchase price of $1.75 per share, including to institutional and strategic investors, as well as the Chairman of Cibus' board of directors (5,714,286 shares).
Neutral
GlobeNewsWire
2 months ago
Cibus, Inc. Announces Proposed Public Offering
SAN DIEGO, June 04, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that it intends to offer shares of its Class A common stock (or common stock equivalents in lieu thereof) in a public offering. All of the securities to be sold in the offering are to be offered by Cibus. The Chairman of Cibus' board of directors, Mr. Rory Riggs, has indicated an interest in purchasing up to $10.0 million of shares of Class A common stock and/or common stock equivalents in this offering. Because such an indication of interest is not a binding agreement or commitment to purchase, Mr. Riggs may elect not to purchase any shares in this offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Charts implemented using Lightweight Charts™